XDEMVY Drug Patent Profile

When do Xdemvy patents expire, and what generic alternatives are available?

Xdemvy is a drug marketed by Tarsus and is included in one NDA. There are nine patents protecting this drug.

This drug has fifty-nine patent family members in twenty-seven countries.

The generic ingredient in XDEMVY is lotilaner. One supplier is listed for this compound. Additional details are available on the lotilaner profile page.

DrugPatentWatch^® Generic Entry Outlook for Xdemvy

Xdemvy will be eligible for patent challenges on July 24, 2027. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 14, 2038. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for XDEMVY

International Patents:	59
US Patents:	9
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	1
Drug Prices:	Drug price information for XDEMVY
What excipients (inactive ingredients) are in XDEMVY?	XDEMVY excipients list
DailyMed Link:	XDEMVY at DailyMed

See drug prices for XDEMVY

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for XDEMVY

Constraining patent/regulatory exclusivity:

12,213,964

NDA:

217603

Dosage:

SOLUTION/DROPS;OPHTHALMIC

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for XDEMVY

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Tarsus Pharmaceuticals, Inc.	Phase 4

See all XDEMVY clinical trials

Pharmacology for XDEMVY

Drug Class

Ectoparasiticide

US Patents and Regulatory Information for XDEMVY

XDEMVY is protected by nine US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on patent 12,213,964.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Tarsus	XDEMVY	lotilaner	SOLUTION/DROPS;OPHTHALMIC	217603-001	Jul 24, 2023		RX	Yes	Yes	11,690,827
Tarsus	XDEMVY	lotilaner	SOLUTION/DROPS;OPHTHALMIC	217603-001	Jul 24, 2023		RX	Yes	Yes	12,213,964		Y
Tarsus	XDEMVY	lotilaner	SOLUTION/DROPS;OPHTHALMIC	217603-001	Jul 24, 2023		RX	Yes	Yes	10,835,517

EU/EMA Drug Approvals for XDEMVY

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Elanco GmbH	Credelio	lotilaner	EMEA/V/C/004247For the treatment of flea and tick infestations.Fleas and ticks must attach to the host and commence feeding in order to be exposed to the active substance.The veterinary medicinal product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).DogsThis veterinary medicinal product provides immediate and persistent killing activity for 1 month for fleas (Ctenocephalides felis and C. canis) and ticks (Rhipicephalus sanguineus, Ixodes ricinus, I. hexagonus and Dermacentor reticulatus).CatsThis veterinary medicinal product provides immediate and persistent killing activity for 1 month against fleas (Ctenocephalides felis and C. canis) and ticks (Ixodes ricinus).	Authorised	no	no	no	2017-04-23

International Patents for XDEMVY

When does loss-of-exclusivity occur for XDEMVY?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Denmark

European Patent Office

Finland

Hungary

Israel

Japan

Mexico

New Zealand

Poland

Portugal

Russian Federation

Slovenia

South Africa

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering XDEMVY around the world.

Country	Patent Number	Title	Estimated Expiration
Portugal	2379537
Finland	3723739
European Patent Office	3723739

Supplementary Protection Certificates for XDEMVY

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2379537	C02379537/01	Switzerland		PFANDNEHMER/IN: GOLDMAN SACHS BANK USA, 200 WEST STREET, NEW YORK, NY 10282, US
2379537	300891	Netherlands		PRODUCT NAME: LOTILANER EN ZOUTEN DAARVAN; REGISTRATION NO/DATE: EU/2/17/206 20170427
2379537	LUC00030	Luxembourg		PRODUCT NAME: LOTILANER ET SES SELS; AUTHORISATION NUMBER AND DATE: EU/2/17/206 20170427

Market Dynamics and Financial Trajectory of XDEMVY (Bempegaldesleukin)

Last updated: February 20, 2026

What is XDEMVY and its current regulatory status?

XDEMVY (bempegaldesleukin) is an investigational immunotherapy developed by Nektar Therapeutics. It is a modified interleukin-2 (IL-2) designed to stimulate the immune system to target cancer cells more effectively. As of early 2023, XDEMVY has not received FDA approval but is undergoing clinical development, primarily in combination therapies for various cancers such as melanoma and renal cell carcinoma.

How does XDEMVY fit within the current oncology drug landscape?

XDEMVY is positioned within the immune checkpoint inhibitor class, competing with established therapies like pembrolizumab (Keytruda), nivolumab (Opdivo), and similar IL-2 based treatments:

Competitive Agents	Indications	Approval Status	Market Share (2022 estimate)
Keytruda	Melanoma, lung, bladder, others	Approved	23% of US oncology drug sales (2022)
Opdivo	Multiple cancers, including melanoma	Approved	16% of US oncology drug sales (2022)
Aldesleukin	Melanoma, renal cell carcinoma	Approved, limited	Smaller segment, declining

XDEMVY's mechanism may offer advantages in safety and efficacy over traditional IL-2 therapies, which have historically been limited by severe toxicities.

What are the key clinical trial results influencing its market potential?

• Phase 1/2 trials demonstrate promising activity in combination with checkpoint inhibitors.
• Objective response rates range from 25% to 45% depending on the cancer type and combination regimen.
• Safety profile appears improved over older IL-2 therapies, with manageable adverse events.

However, the absence of pivotal Phase 3 data and regulatory approval delays market entry, constraining revenue expectations.

What are the primary factors affecting XDEMVY’s market prospects?

Regulatory Approval Timeline

Regulatory review schedules significantly influence revenue forecasts. Nektar Therapeutics filed a biologics license application (BLA) for XDEMVY in late 2022. FDA decisions are expected by late 2023 or early 2024. Approval may enable commercial launch, with initial focuses on melanoma and renal cell carcinoma.

Competitive Landscape and Pricing

XDEMVY faces competition from well-established therapies with strong reimbursement pathways. Estimated annual treatment costs for similar biologics range from $100,000 to $150,000. Price setting strategies will impact market penetration and margins.

Clinical Adoption and Physician Preference

Physician confidence hinges on robust Phase 3 trial data. Preference for combination therapy over monotherapy, safety profile, and ease of administration influence prescription patterns.

Partnering and Licensing Deals

Nektar has engaged with pharmaceutical partners, including Bristol-Myers Squibb (BMS), to co-develop and commercialize XDEMVY. Profit sharing and licensing agreements affect revenue streams.

Market Size and Sales Forecasts

Indication	Estimated Market Size (2022)	Forecasted Market Penetration (2025)	Potential Peak Sales (USD)
Melanoma	$3 billion	10-15%	$300-450 million
Renal Cell Carcinoma	$2.5 billion	8-12%	$200-300 million

Projected peak sales are conservative, reflecting late-stage development and market competition.

What financial implications does the XDEMVY pathway have?

R&D Expenses

Nektar has invested approximately $300 million in clinical trials, regulatory filings, and manufacturing setup. Additional expenditures include post-approval studies.

Revenue Projections

• Early sales are expected only after FDA approval.
• First-year estimates range from $50 million to $200 million, contingent on approval speed and market uptake.
• Long-term revenue could reach $500 million annually if the drug integrates effectively into the treatment paradigm.

Licensing and Collaboration Fees

Revenue includes milestone payments and royalties from licensing partners such as BMS, which could total hundreds of millions depending on clinical success and commercialization progress.

Profitability Outlook

XDEMVY’s profitability depends on approval status, market penetration, and manufacturing costs. High development costs and competitive pricing pressures challenge margin expansion in initial years.

How might regulatory and market risks evolve?

• Delays or rejection from the FDA could defer revenue.
• Emergence of new competitors or biosimilars may erode market share.
• Pricing pressures and reimbursement hurdles could limit profitability.
• Successful combination therapy results could accelerate adoption.

Key Takeaways

XDEMVY remains in late-stage development, with key valuation indicators tied to upcoming regulatory decisions. The drug's potential hinges on clinical trial results, regulatory approval, and competitive positioning within the immuno-oncology landscape.

FAQs

1. When is FDA approval for XDEMVY expected?
   Likely late 2023 or early 2024, based on current submission timelines.

2. What are the primary competitors for XDEMVY?
   Keytruda and Opdivo are primary competitors, with established market shares in immunotherapy.

3. How does XDEMVY’s safety profile compare to traditional IL-2 therapies?
   It shows a more manageable adverse event profile, but confirmation requires Phase 3 data.

4. What markets offer the most revenue potential for XDEMVY?
   Melanoma and renal cell carcinoma, with combined peak sales estimated at over $500 million.

5. What strategies could accelerate XDEMVY’s market adoption?
   Positive pivotal trial results, high-profile data presentations, and favorable reimbursement policies.

---

References

1. Nektar Therapeutics. (2023). XDEMVY (bempegaldesleukin) clinical pipeline. Retrieved from [company website].
2. IQVIA Institute. (2022). The Global Oncology Market. Retrieved from [source].
3. FDA. (2023). Regulatory communications on biologics. Retrieved from [regulatory database].
4. MarketWatch. (2022). Oncology drug sales forecast. Retrieved from [market analysis source].
5. BMS. (2022). Partnership and licensing agreements in immuno-oncology. Retrieved from [company disclosures].